Search

The article discusses the LoTam clinical trial, comparing low-dose tamoxifen to standard hormonal therapy for post-menopausal women with hormone-positive, HER2-negative early-stage breast cancer. Tamoxifen blocks estrogen activity, while aromatase inhibitors prevent estrogen formation. The trial aims to assess recurrence-free interval, endocrine therapy adherence, adverse events, survival rates, and quality of life. The study is still in the recruitment phase, with specific eligibility criteria for participants. [Extracted from the article]

Havah Therapeutics Pty Ltd. has been issued a patent for pharmaceutical formulations and systems for the delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles. The patent aims to address the need for altering the DHT to estradiol ratio within tissues, particularly in women with high mammographic breast density, to reduce the risk of breast cancer development. The invention also targets the treatment of breast pain, tissue-specific autoimmune inflammatory conditions, and the reduction of mechano-transduction in breast cells to lower the risk of malignant transformation. [Extracted from the article]

The patent application by Stephen Nigel Birrell discusses methods for reducing mammographic breast density and breast cancer risk by administering androgenic agents and aromatase inhibitors. The application highlights the importance of addressing breast density and stiffness in relation to breast cancer risk, as well as the need for better treatments for breast pain and macromastia. The methods proposed aim to reduce breast tissue elasticity, decrease mechano-transduction on the genome of breast cells, and stabilize androgen receptor expression, among other outcomes. The application also emphasizes the potential benefits of these methods for pre-menopausal, peri-menopausal, and post-menopausal women. [Extracted from the article]

Researchers from Shanghai Jiao Tong University School of Medicine conducted a study on endometriosis, a chronic inflammatory condition affecting women of reproductive age. The study focused on the role of Nicotinamide N-methyltransferase (NNMT) in endometriosis, finding that NNMT is overexpressed in endometrial stromal cells (ESCs) of patients with endometriosis. Inhibition of NNMT reduced ESC proliferation, migration, and invasion, suggesting a potential therapeutic target for endometriosis treatment. The study concluded that NNMT overexpression induced by estrogen and macrophage interaction contributes to ESC proliferation in endometriosis. [Extracted from the article]

Researchers from the University of Baghdad have conducted a study on the association of Activin A levels and body mass index with human CGB in ectopic pregnancies and missed abortions. The study included 120 participants, with findings indicating that women with ectopic pregnancy and missed abortion had higher levels of Activin A and human chorionic gonadotropin beta compared to healthy controls. The research suggests that serum Activin A can serve as an indicator for ectopic pregnancy and missed abortion, while obesity represented by BMI does not significantly affect these conditions. The study also proposes that serum Beta-HcG levels may be a novel biomarker for assessing women with ectopic pregnancy. [Extracted from the article]

Researchers at Saarland University Hospital conducted a retrospective cross-sectional study to investigate the relationship between serum estradiol levels, ultrasound follicle count, number of oocytes retrieved, and their impact on in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) treatment outcomes. The study found a significant correlation between serum estradiol levels, sonographic follicle count, and number of oocytes retrieved. Age was inversely associated with sonographic follicle count and number of oocytes, while BMI, nicotine, and stimulation protocol showed no significant association with the observed parameters. The research suggests that optimizing oocyte retrieval procedures based on follicle numbers could improve treatment outcomes. [Extracted from the article]

A recent study explored the effects of probiotics on myocardial infarction (heart attack) and depression-like behaviors, focusing on sex-specific responses in male and female rats. The probiotics Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 were administered to the rats, showing a reduction in infarct size in female rats and behavioral benefits in male rats. The study emphasizes the importance of considering sex differences in future probiotic treatments for heart attacks. For more information, the full article can be accessed at https://doi.org/10.3390/biomedicines12112511. [Extracted from the article]

The article explores the effects of 17-estradiol treatment on the endocrine system through single-nucleus transcriptomic sequencing of the hypothalamus in aged male Norway brown rats. The study reveals that 17-estradiol treatment attenuates cellular stress and metabolic changes associated with aging in neurons, impacting various functions related to food intake, reproduction, blood pressure, stress response, and electrolyte balance. The treatment also increases serum Oxytocin levels and activates the hypothalamic-pituitary-gonadal axis, with potential side effects observed in Crh neurons. The research suggests that the HPG axis and energy metabolism are key targets of 17-estradiol in the male hypothalamus, highlighting the importance of supervised clustering of neurons for treatment assessment. [Extracted from the article]

The article discusses the impact of vaginal estrogen therapy (VET) initiation on disease-free survival (DFS) in women with a history of non-metastatic breast cancer (BC). The study utilized data from the French National Health Data System to emulate target trials and found that VET initiation did not decrease DFS in patients with hormone receptor (HR)-positive tumors treated with tamoxifen. However, VET initiation might decrease DFS in patients treated with aromatase inhibitors, with estriol leading to a more pronounced decrease in DFS than promestriene. The preprint has not been peer-reviewed and provides valuable insights into the potential effects of VET on oncological outcomes in BC patients. [Extracted from the article]

A recent study conducted by the University of Copenhagen explored the relationship between reproductive hormones and ovarian and uterine morphology in infant girls during minipuberty. The research, which involved 302 healthy infant girls, found correlations between various reproductive hormones and ovarian activity, suggesting the establishment of negative feedback in the female hypothalamic-pituitary-gonadal axis during minipuberty. The study provides normative data on infant ovarian and uterine morphology that can be directly applied in a clinical setting. [Extracted from the article]

Scientists from the University of Sharjah have discovered new ways to improve breast cancer treatment, particularly for the aggressive triple-negative breast cancer. Their research, published in the European Journal of Pharmacology, focuses on the role of HDAC6 in lowering progesterone receptors, making breast cancer cells less responsive to hormonal therapies. By targeting HDAC6, researchers aim to enhance the sensitivity of aggressive breast cancer cells to hormonal therapies, offering hope for more effective treatment options for patients with challenging breast cancer subtypes. [Extracted from the article]

The article discusses a clinical trial, NCT06657105, conducted by AstraZeneca to assess the effect of multiple doses of baxdrostat on the pharmacokinetics of a single dose of combined oral ethinyl estradiol and levonorgestrel in healthy female participants of non-childbearing potential. The study aims to evaluate the safety and tolerability of baxdrostat during the trial period. The trial is set to be completed by January 17, 2025, and will involve 48 participants. The study design is interventional, with a non-randomized allocation and a sequential intervention model. [Extracted from the article]

A study published in Health & Medicine Week explores the impact of knocking out the regulator of G-protein signaling 2 (RGS2) in CD4+ T cells on ovarian function and immune cell differentiation in female mice. The research found that RGS2 knockout in CD4+ T cells led to increased oocyte ovulation and higher levels of anti-inflammatory T cells in the ovary and uterus, along with elevated concentrations of estradiol and progesterone in the serum. The study suggests that RGS2 plays a crucial role in reproductive outcomes and calls for further investigation into its effects on fertility and implantation. [Extracted from the article]

A recent study conducted at the University of Jos Teaching Hospital in Nigeria explored the use of serum inhibin B as a biomarker for male infertility. The research focused on its correlation with sperm count and found a significant positive relationship. The study concluded that serum inhibin B is a reliable biomarker for assessing male infertility, with the inhibin B/FSH ratio showing superior diagnostic accuracy for non-obstructive azoospermia and oligozoospermia. This research provides valuable insights into the evaluation of spermatogenic function in male infertility diagnosis. [Extracted from the article]

Researchers at Yunnan Minzu University in Kunming, China, have developed a novel self-powered electrochemical biosensor for the precise detection of 17 beta-estradiol (E2) using enzymatic biofuel cells. The biosensor integrates dual-enzyme cascade amplification and bioconjugate technology, achieving exceptional sensitivity with a detection limit of 3.3 pg mL-1. This research has significant potential for applications in food and environmental safety, serving as a prototype for a mobile and on-site bioassay system. The study was funded by various organizations and has been peer-reviewed, offering valuable insights into emerging technologies in bioengineering and biotechnology. [Extracted from the article]

Researchers at Shanxi University in the People's Republic of China have developed a highly sensitive electrochemical aptasensor for detecting 17 beta-estradiol (E2) using gold particles (Au NPs) signal amplification. The sensor exhibited excellent analytical performance with high sensitivity, selectivity, and stability, with a detection limit for E2 of 0.053 pM and a linear response ranging from 0.1-200 pM. The research, funded by various organizations including the National Natural Science Foundation of China, concluded that the sensor showed promising results when applied to real environmental samples. This study was published in the Microchemical Journal and can be accessed for further information. [Extracted from the article]

Researchers at Daiichi University of Pharmacy in Fukuoka, Japan, conducted a study on the solubilization behavior of medroxyprogesterone (MP) in gemini surfactant micelles, comparing it with progesterone. The study found that MP integrates more deeply into the micellar core due to its unique structural features, which promote enhanced interactions with hydrophobic regions of the micelle. The research suggests that these insights into the solubilization dynamics of MP could have implications for diverse drug delivery applications. For more information, the full article is available in Molecules, and the researchers can be contacted at Daiichi University of Pharmacy in Japan. [Extracted from the article]

A recent report from Jiangsu University in Zhenjiang, People's Republic of China, discusses the detection of 17 beta-Estradiol (E2) and its impact on human health and ecosystems. The study highlights the use of paper-based analytical devices (PADs) as promising tools for E2 detection due to their portability, cost-effectiveness, and rapid results. Despite significant progress, challenges such as sensitivity and commercial viability remain, and the research suggests a strategic roadmap for the future development and commercialization of PADs. For more information, readers can refer to the article "A Comprehensive Review of Paper-based Analytical Devices for 17b-estradiol Detection: Current Status and Future Perspectives" published in Microchemical Journal. [Extracted from the article]

A study conducted by Charite - University Medicine Berlin examined the effects of estradiol and progesterone administration on fear extinction in healthy pre-menopausal women. The research found that estradiol administration affected the extinction of conditioned fear responses, leading to a stronger return of fear. These findings suggest that estradiol levels may influence the success of exposure therapy in treating anxiety disorders. The study involved 116 women and was published in Translational Psychiatry in 2024. [Extracted from the article]

A report from the Center for Reproductive Medicine in Moscow, Russia, compared the outcomes of progesterone-modified fixed natural cycle (P4mNC) and hormone replacement therapy (HRT) protocols for frozen embryo transfer cycles. The study found no significant differences in clinical outcomes, including live birth rate, clinical pregnancy rate, and miscarriage rate, between the two groups. The research suggests that P4mNC-FET cycles offer comparable results to traditional HRT-FET cycles with more flexibility in the timing of embryo transfer. This study has been peer-reviewed and provides valuable insights into assisted reproductive techniques. [Extracted from the article]

A study conducted by Universiti Kebangsaan Malaysia explored the estrogenic activity of Achyranthes aspera L. on estrogen-responsive breast cancer cells. The research identified twelve phenolics in the active fraction of Achyranthes aspera L., which showed potential interactions with the hERa receptor. The study suggests that Achyranthes aspera L. may have estrogenic properties and could be beneficial in managing menopausal-related issues. For more information, the full article can be accessed for free at https://doi.org/10.1016/j.heliyon.2024.e38792. [Extracted from the article]

A recent study conducted at the University of Michigan focused on the impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain. The research, supported by Sumitomo Pharma Switzerland GmbH and Pfizer Inc., found that women treated with relugolix CT experienced significant improvements in pain domain scores and overall quality of life over a 104-week period. The study concluded that relugolix combination therapy led to sustained reduction of endometriosis-associated pain and improvements in functioning and health-related quality of life. [Extracted from the article]

Researchers at Tongji University in Shanghai, China, conducted a study on the expression of carbonic anhydrase IX (CAIX) protein in hemangioblastoma of the central nervous system. The research aimed to explore the potential application of CAIX in pathological diagnosis and differential diagnosis. The study found significant differences in CAIX and alpha-inhibin expression in hemangioblastoma compared to other central nervous system neoplasms, suggesting that CAIX immunohistochemistry could aid in the diagnosis of hemangioblastoma. The combination of CAIX with EMA was deemed useful for the diagnosis and differential diagnosis of hemangioblastoma. [Extracted from the article]

A recent study conducted at Shiraz University of Medical Sciences in Iran explored the effects of L-tartaric acid on ovarian histostereological and hormonal changes in an animal model of Polycystic Ovary Syndrome (PCOS). The study found that PCOS led to significant alterations in ovarian tissue and hormone levels, but the administration of tartaric acid helped restore these effects. The research suggests that tartaric acid could be a potential novel strategy for managing PCOS, although further studies are needed to confirm these findings. [Extracted from the article]

A recent study conducted at Charite University Hospital and School of Medicine in Berlin, Germany, explored the predictive value of estradiol (E2) related parameters on the incidence of gestational diabetes mellitus (GDM) in women undergoing fresh embryo transfer. The study identified an optimal E2/follicle (E2/F) ratio threshold of 246.03 pg/ml on the day of human chorionic gonadotropin (hCG) administration, which was associated with lower rates of GDM and ovarian hyperstimulation syndrome (OHSS). The research concluded that an E2/F ratio over 246.03 pg/ml is significantly linked to a reduced risk of both GDM and OHSS, making it a superior predictive biomarker compared to other E2-related parameters. [Extracted from the article]

A recent study conducted at Omsk State Pedagogical University in Russia focused on the expression of the MUC1 family of transmembrane glycoproteins in breast cancer patients. The research found that levels of MUC1 in the saliva of patients with HER2-positive breast cancer were significantly lower compared to healthy controls. The study also highlighted a correlation between aggressive tumor growth, high levels of pro-inflammatory cytokines, low levels of free estradiol, and suppressed expression of salivary MUC1. For more information, the full article is available in the journal Cancers. [Extracted from the article]